Biotech China 2014

Drug Design: Merck

Total Score People Score Events Score
118 101 90
Date Event Presentation Speakers
February 20, 2012 Advances and Progress in Drug Design Noticing the unnoticed: bridging structural data and drug design Jose Duca
Biophysics in drug discovery: integrative use of structural, kinetic and thermodynamic data Matthias Frech
October 26, 2010 Biofit 2010 The dos and don’ts of new partnering business models Manfred Horst
August 25, 2010 Co-Development of Drugs and Diagnostics Choosing a Biomarker Partner Cynthia Gawron-Burke
July 11, 2010 Translational Cancer Medicine 2010 (USA) The biomarker roadmap: How to integrate biomarker and compound discovery for early clinical decision making Pearl S. Huang
Why current ways of working together as patients, clinicians, and scientists could ultimately fail Stephen H Friend
June 23, 2010 Structure-Based Drug Design TABLE 4: Do We Get the Most Out of the Structural information in the PDB? Tips and Lessons Learned José Duca
Chairperson’s Remarks José Duca
May 19, 2010 Towards Personalized Cancer Medicine Integrative Genomic Models of Disease, Use of Contributor Networks Stephen H Friend
SESSION IV: Biomarkers for Prognosis/Response: Impact on Clinical Trials Stephen H Friend
Molecular Profiling of Pre-Clinical and Clinical Models: Informing the Development of Rational Combinations James Watters
PANEL DISCUSSION Stephen H Friend
May 4, 2010 Biomarker World Congress 2010 Identification of a Transcriptional Biomarker of Target Engagement and Use in Oncology Early Clinical Development Samuel C. Blackman
Practice and Pitfalls of Open Source Precompetitive Collaboration on Biomarkers John A. Wagner
From Biomarker Strategies to Biomarker Activities and Back Alain van Gool
April 28, 2010 HCV Drug Discovery Recent Developments in HCV NS3/4A Protease Inhibitor Nigel Liverton
April 28, 2010 Kinase Inhibitor Chemistry Featured Presentation Discovery of Novel Kinase Inhibitors Using Structure-Based Design Jose Duca
February 22, 2010 2010 PERSONALIZED MEDICINE PARTNERSHIPS CONFERENCE Merck’s Licensing Strategy – Oncology Partnerships and Personalized Medicine Linda Egger
February 1, 2010 4th DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE What Companies Look for in a Licensing Partner Susan P. Rohrer
November 2, 2009 Track 4: Fourth Annual GPCR-based drug discovery CGRP Receptor Antagonists for the Acute Treatment of Migraine Donnette Staas
November 2, 2009 Seventh Annual Strategic Resource Management Designing Flexible Portfolio Management Processes Christine Cioffe
October 13, 2009 Fourth Annual Drug Repositioning Summit Knowledge Management Technologies for Drug Repurposing Natalia Novac
September 29, 2009 Paediatric Drug Development Industry Viewpoint: Examining the impact of the EMEA guidelines on paediatric drug development Jan Gross
Designing a combined approach to global paediatric healthcare challenges Vijay Tammara
September 24, 2009 Track 4: Bridging Silos in Biomarker Development : Seventh Annual Protein Biomarkers Proteomics - From Basic Research to the Clinic Ronald C. Hendrickson
August 24, 2009 Specialized Protein Expression Systems Opening Chairperson’s Remarks Fubao Wang
August 18, 2009 Second Annual Pre-Clinical/Clinical Development of Immunotherapies and Vaccines Risk Management in Vaccine Development Programs Adrian Dana
August 17, 2009 Fourth Annual Novel Vaccines: Design & Development Plenary Featured Presentation Risk-Based Modelling for Vaccine Supply Chain Capacity Assessment Susan Behrens
August 5, 2009 Drug Safety Strategies to De-Risk Compounds An in vitro and in vivo Evaluation of the Off-Target Profile of the CETP Inhibitor, Torcetrapib Michael J. Forest
August 3, 2009 Oligonucleotide Therapeutics - From Concept to Implementation Agenda RNA Therapeutics - Are We Leveraging on the Promise? Paul Burke
July 1, 2009 Advances in Oral Dose Manufacturing Assessing the Benefits and Liabilities of Using Amorphous Materials during the Development Process V Brett Cooper
Controlled Release Using Solid Oral Dosage Form Shaun Fitzpatrick
Quality by Design: DoE Case Study for a Roller Compaction Process Klaus Kunath
June 10, 2009 Second Annual Hepatotoxicity and Drug Safety In Vitro - In Vivo Correlations of Drug-Induced Liver Injury Jinghai Xu
Investigation of Drug-Induced Hepatotoxicity from a Drug Metabolism Perspective Wei Tang
June 9, 2009 Inaugural The Expanding Impact of New Animal Models in Drug Safety Predictive Methodologies in Ophthalmic Pharmaceutical Discovery and Safety Robert L. Peiffer
Closing Panel Discussion: What can we do to Create Better Testing Models so that Toxicity Results in Animals are more Predictive? Robert L. Peiffer
June 9, 2009 RNAi for Target Identification and Validation A High-Throughput Chemical Biology Approach to Identify Modulators of the Hypoxia Inducible Factor (HIF) Pathway Marc Ferrer
June 9, 2009 Cell and Tissue-Based Assays for HTS Data Analysis in RNAi High-Throughput Screens Xiaohua Douglas Zhang
Evaluation of Putative GPCR Antagonists Using the CellKey System David J. Bell, Department of Automated Biotechnology, Merck & Company David J. Bell
June 9, 2009 Third Annual Cardiotoxicity and Drug Safety Inward Rectifier Kir2.1 PatchXpress Assay as a Model of Cardiac IK1 John P. Imredy
June 9, 2009 Targeting Pain with Novel Therapeutics Nav1.7 Inhibitors – Discovery and Development Joseph L. Duffy
June 8, 2009 RNAi for Functional Screens OPTIMIZING RNAi DELIVERY FOR IN VITRO APPLICATIONS Shane Marine
June 1, 2009 Combination Products Regulatory Strategy for Combination Products Chitkala Kalidas
May 11, 2009 Patient Recruitment in Clinical Trials Do You Have an Implementable Protocol? Brendan O’Neill
Table #4: How Can Operations Influence Patient Definition and Protocol Design? Brendan O’Neill
April 21, 2009 3rd Annual Clinical Trials in Emerging Economies Experience in conducting clinical Trials in Central and Eastern Europe Eva Lapkova
April 21, 2009 16th Annual Conference Regulatory Affairs in Central and Eastern Europe Morning coffee and networking Jinghai Xu
April 7, 2009 Inaugural HIV Inhibitors KEYNOTE PRESENTATION: The Discovery of Novel HIV Integrase Inhibitors Joseph P. Vacca
KEYNOTE PRESENTATION: The Discovery of Novel HIV Integrase Inhibitors Joseph P. Vacca
March 9, 2009 Drug Development Latin America Organizer’s Welcome and Chairperson’s Remarks Jorge Rodriguez Larrain
Chairperson’s Remarks Jorge Rodriguez Larrain
Adaptative Designs (Phase I - III): Regulatory Challenges and Opportunities in Latin America Jorge Rodriguez Larrain
February 23, 2009 4th Investigator Relationship Management NEW APPROACH TO TRIALS Ernesto Aycardi
February 23, 2009 Advances and Progress in Drug Design VIII KNOWLEDGE BASED DRUG DESIGN Matthias Frech
February 17, 2009 Pharma/Biotech Patent Litigation Conducting Complex Multi-Jurisdictional Patent Litigation: Choosing Your Litigation Tony Rollins
February 9, 2009 Immunogenicity for Biologics 2009 Risk-based immunogenicity testing strategy Daniel Kramer
January 28, 2009 Electronic Laboratory Notebooks INTEGRATION OF ANALYTICAL WORKFLOW INTO ELNs : Supporting the research chemists with valid information and data Jan Hauß
January 26, 2009 7th Annual Partnering with Central Labs Track B : Utility of Imaging in Clinical Trials- Strategies for Success P David Mozley
Track B : Building the Imaging Lexicon for Rate Cards to Improve Industry Consistency P David Mozley
PANEL DISCUSSION : Comparing Approaches: Preferred Providers vs Competitive Bidding, What is your Best Choice? Diane Stinson
January 12, 2009 Model Based Drug Development KEYNOTE PRESENTATION : The Use of Decision Analytic Paradigms to Reduce Uncertainty in Drug Development Anis Khan, Rajesh Krishna
January 5, 2009 High Content Analysis Insight into HCS Data Stream: Analytical Strategy and Applications Ansuman Bagchi
Statistical Analysis of High-Content Data: Harnessing the Full Data Matrix Amir A Handzel
High-Throughput High-Content Screening in Primary and Stem Cells Francesca Santini
December 9, 2008 3rd Annual Congress Strategies to enhance Solubility and Drug Absorption Salt selection as a tool to enhance solubility and drug absorption Christoph Saal,
December 2, 2008 The 8th World Drug Discovery & Development Summit 2008 APPLICATIONS OF SYSTEMS BIOLOGY IN TARGET IDENTIFICATION AND TOXICITY SCREENING Jinghai Xu
Chairman's introduction Jinghai Xu
November 26, 2008 4th Annual Audits and Inspections for Clinical Trials and Pharmacovigilance Getting the most out of audits – best practice in pharmacovigilance audits Veerle Noppen,
November 17, 2008 BIO-Europe 2008 Rethinking R&D: Can Big Pharma Address the Productivity Gap through Earlier-Stage Collaborations? Barbara Yanni, Bernhard Kirschbaum
November 12, 2008 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements Asset Spin-Outs: Overcoming Challenges in Negotiating Out Licensing by Pharma and Big Biotech Cynthia J Zarsky
November 11, 2008 Stability Testing for Biologics How to calculate product expiry after excursion Timothy , Schofield
November 11, 2008 5th Annual Registration of Generics Summit Examining the latest changes in European policy Howard Rosenberg,
November 5, 2008 DIA's 6th Canadian Annual Meeting: Benefit and Risk Management: An Evolution in Progress TRACK 2 : BEST PRACTICE IN GLOBAL PHARMACEUTICAL RISK MANAGEMENT PLANNING Mary , Frances Schubert
TRACK 2 : BEST PRACTICE IN GLOBAL PHARMACEUTICAL RISK MANAGEMENT PLANNING Mary , Frances Schubert
October 23, 2008 Adaptive Clinical Trial Designs Problem Solving Break-out Sessions Bruce Binkowitz
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics New(er) Tools for Rapid Metabolite Identification Kevin Bateman
Minimizing Drug Toxicities During Drug Discovery and Development | Altas Ballroom (Town & Country/San Diego) Tom Baillie
Unusual Interspecies Differences in the Metabolism of a Cathepsin K Inhibitor Deborah Nicoll-Griffith
Unusual Interspecies Differences in the Metabolism of a Cathepsin K Inhibitor Deborah Nicoll-Griffith
September 29, 2008 Genomic Biomarkers Building a Biomarker Information Pipeline and Enabling Translational and Personalized Medicine: Leveraging Industry Standards to Bring Omics Closer to Medicine Martin D. Leach
Pharmacogenomics Data: Transmission and Submission Joyce Hernandez
September 29, 2008 Biomarker Data Analysis Building a Biomarker Information Pipeline and Enabling Translational and Personalized Medicine: Leveraging Industry Standard to Bring Omics Closer to Medicine Martin D. Leach
September 29, 2008 Metabolic Biomarkers Building a Biomarker Information Pipeline and Enabling Translational and Personalized Medicine: Leveraging Industry Standards to Bring Omics Closer to Medicine Martin D. Leach
July 20, 2008 WORLD SUMMIT OF ANTIVIRALS Combating Severe Viral Infections Session 6: Omics and System Biology for Viral Infectious Diseases Xiaohua Douglas Zhang
Analytic Methods in Genome-Scale RNAi Research with Applications in Drug Discovery for Viral Infectious Diseases Xiaohua Douglas Zhang
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Decision-Making in Oncology Drug Development Stephen H Friend
Panel Discussion Stephen H Friend
May 4, 2008 Impact China IV: Pharmaceutical R&D Global Summit Keynote Address: Chinese SFDA and Global Drug Development - Quality, Science and Speed Zili Li
Elective: Track A: Novel Advancements and Developments Originating in China: Engineering Anti-ADDLs Antibodies for Treatment of Alzheimers Disease Zhiqiang An
March 31, 2008 China 2008 Pharmaceutical R&D Summit Track I Discovery to PreClinical Development –Case studies of Licensing & Partnering in China Chairperson’s Opening Remarks Dr. Bharatt M. Chowrira
March 30, 2008 Nuclear Receptors: Steroid Sisters Workshop 2 - Hot Topics: Repression/Regulation of Nuclear Receptor Function Beatrice D. Darimont
March 30, 2008 Nuclear Receptors: Orphan Brothers Workshop 2 - Hot Topics: Repression/Regulation of Nuclear Receptor Function Beatrice D. Darimont
March 29, 2008 Computer-Aided Drug Design Successful Application of Modeling in Drug Design: Case Studies Kate Holloway
March 25, 2008 TRENDS IN DRUG SAFETY Innovative Medicines for Europe Phil Hewitt
March 18, 2008 MedChem India Discovery of IsentressTM, First in Class HIV Integrase Inhibitor for the Treatment of HIV Infection Vincenzo Summa
March 16, 2008 Advances in Cancer Research: From the Laboratory to the Clinic Applications of Molecular Profiling to RNA Therapeutics Aimee L Jackson
February 19, 2008 Screening Europe Track A Neglected Diseases: Building a Lead Discovery Engine Dominique Perrin
February 19, 2008 MedChem Europe HDAC Inhibitors: Bench to Bedside Thomas A. Miller
February 17, 2008 GRC - Peptides, Chemistry & Biology Of Ligands for Melanocortin Receptors Maria Bednarek
January 18, 2008 xmjqwrqi Interpreting the Guidelines on Risk Management Plans Robert G. Sharrar
December 10, 2007 Dissolution Testing NOVEL IN-VITRO SCREENING OF EXAPIENTS FOR EARLY DEVELOPMENT OF LOW-SOLUBILITY COMPOUND FORMULATIONS Maria T. Cruanes
EXAMINING OUTLIERS IN A BIOAVAILABILITY STUDY Jason Liao
INTERACTIVE PANEL DISCUSSION Maria T. Cruanes
December 4, 2007 7th World Drug Discovery & Development Summit 2007 Conference room 2 PREDICTIVE TOXICITY SCREENING PRIOR TO DEVELOPMENT Dr. Stefan Otto Mueller
Conference room 2 HIGH CONTENT SCREENING Jinghai Xu
November 29, 2007 Fourth Annual In Vivo Molecular Imaging: Bridging the Gap from Discovery to Clinical Applications Nov (29-30) Pre-Clinical Imaging (08:25-12:15) John Atack
Pre-Clinical Imaging: PET Imaging and Occupancy Measurements in Rat, Monkey and Humans (08:30-09:00) John Atack
November 28, 2007 Second Annual Portfolio Management: Creating a Portfolio for Optimal Productivity Nov (28-29) BRIDGING PLENARY SESSION : CASE STUDY: Integration of Resource Capacity Management and Decision Analysis into the Portfolio Decision Process (16:45-17:30) Suzanne K. Brown
November 27, 2007 Fifth Annual Strategic Resource Management: The Key to Increasing R&D Productivity Nov (27-28) Discrete Event Modeling and Simulation to Assess the Resource Impact of Strategic Investment Opportunities (16:00-16:45) Matt Hendricks
ROUNDTABLE DISCUSSIONS TABLE 4: Does Project and Portfolio Prioritization Really Lead to Value Creation? (16:45-18:00) Suzanne K. Brown
INTERACTIVE PANEL DISCUSSION: Creating a Process to Successfully Transfer Internal and External Resources among Projects (11:45-12:30) Matt Hendricks
BRIDGING PLENARY SESSION: CASE STUDY: Integration of Resource Capacity Management and Decision Analysis into the Portfolio Decision Process (16:45-17:30) Suzanne K. Brown
November 7, 2007 Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13) Session 1: Keynote Forum (09:30 -12:00) Dr. Bharatt M. Chowrira
Session 1: Embracing Cross-Border Alliances to Expand and Advance Drug Discovery Activities (10:00-10:30) Dr. Bharatt M. Chowrira
Session 4: (Part One) Anti-Infectious Drug Discovery & Development (I) (Part Two) RNAi & Gene: Applications in Drug Discovery and Therapeutics (13:30-17:05) Dr. Bharatt M. Chowrira
Session 4: RNAi-Based Therapeutics- The Promise and Challenges (15:00-15:20) Dr. Bharatt M. Chowrira
Session 9: Innovative Metabolic Diseases Drug Discovery & Development (13:30-17:05) Ruojing Yang
Session 9: RNA Interference for Target Identification and Validation (13:30-13:50) Ruojing Yang
November 5, 2007 Bio-Pharma Alliance Summit Nov (05-06) Best Practices in Building Successful Biotech-Big Pharma Alliances –Aligning Expectations and Creating Effective Biotech-Big Pharma Communications (13:15-13:55) James Philipson
October 25, 2007 Pain Therapeutics Summit 2007 Workshop concludes / Conference registration begins Catherine Abbadie
October 17, 2007 Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18) POTASSIUM CHANNELS AND DISEASE (14:10-15:45) James Herrington
POTASSIUM CHANNELS AND DISEASE: Potassium Channels of the Pancreatic Beta-cell and Their Regulation of Insulin Secretion (15:15-15:45) James Herrington
October 17, 2007 Inaugral Nuclear Harmone Receptors Modulators: Targets for Drug Discovery Oct (17-18) DISCOVERY CHEMISTRY (08:35-12:55) H. Blair Wood
DISCOVERY CHEMISTRY: Selective PPAR gamma Modulators for the Treatment of Type 2 Diabetes (09:10-09:40) H. Blair Wood
October 16, 2007 Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17 SESSION I: LAYING THE GROUND WORK FOR EARLY DECISION MAKING (13:45 - 19:00) Jerald S. Schindler
SESSION I: Co-Chairperson’s Opening Remarks (13:50 - 14:00) Jerald S. Schindler
SESSION II: REGULATORY PERSPECTIVES AND LESSONS LEARNED FROM CONDUCTING STUDIES WITH ADAPTIVE TRIAL DESIGNS (08:30-11:15) Jerald S. Schindler
SESSION II: FDA's Perspective on Adaptive Trial Designs (09:15-09:45) Jerald S. Schindler
CASE STUDIES (11:15-14:45) Xiaoyin Frank Fran
CASE STUDY: A Phase 2b Adaptive Dose-Finding Trial of a Novel Compound to Treat Acute Migraines (15:45-16:15) Xiaoyin Frank Fran
October 16, 2007 Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17) Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Lex Van der Ploeg, Shama Kajiji
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) In vitro RNAi Screening Strategies (08:30-10:40) Marc Ferrer
In vitro RNAi Screening Strategies: Genome-Wide siRNA HTS: Multi-readout and Multi-temporal Assays to Identify Physiologically Relevant Genes (09:10-09:40) Marc Ferrer
Keynote Introduction; Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Lex Van der Ploeg, Shama Kajiji
October 15, 2007 2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16) ADDRESSING THE VALIDATION BOTTLENECK: Chairperson’s Remarks (11:10-11:15) Peter DePhillips
October 15, 2007 Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17) CASE STUDIES OF PRACTICAL SYNTHESIS (13:30-18:30) Cheng-yi Chen
CASE STUDIES OF PRACTICAL SYNTHESIS: Catalytic, Enantioselective Synthesis of Taranabant, a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity (14:40-15:10) Cheng-yi Chen
BIOCATALYSIS FOR CHEMICAL PROCESS DEVELOPMENT (08:55-12:00) Paul N. Devine
BIOCATALYSIS FOR CHEMICAL PROCESS DEVELOPMENT: Biocatalysis in Process Research (09:00-09:30) Paul N. Devine
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) PROFILING TO OPTIMIZE EFFICACY (08:30-14:00) Berta Strulovici
PROFILING TO OPTIMIZE EFFICACY: Panel Discussion - The Value of Doing Systems Biology after HTS (12:15-12:45) Berta Strulovici
October 2, 2007 IVT 's Lab Week Building Science into Stability Studies Yan Wu
September 24, 2007 12th Annual Drug Delivery Technologies & Deal Making Track B: Partnering at Merck to Facilitate Delivery Challenges Kimberly Folander
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Eight Annual Metabolic Biomarkers; METABOLITE BIOMARKERS OF TOXICITY (13:30-15:00) Qiuwei Xu
Eight Annual Metabolic Biomarkers; METABOLITE BIOMARKERS OF TOXICITY: NMR Metabolomics: Metabolites, Mechanisms, and Pathways (13:30-14:00) Qiuwei Xu
Third Annual Toxicity Biomarkers; METABOLITE BIOMARKERS OF TOXICITY: NMR Metabolomics: Metabolites, Mechanisms, and Pathways (13:30-14:00) Qiuwei Xu
Third Annual Toxicity Biomarkers; METABOLITE BIOMARKERS OF TOXICITY (13:30-15:00) Qiuwei Xu
September 10, 2007 Drug Development In China: Strategies for launching Discovery and Development activities SPECIAL PRESENTATION: CASE STUDY: Building a New Model of Regulatory Agency Interaction in China (08:15-09:00) Zili Li
Interactive Panel Discussion#3 (11:30-12:15) Zili Li
Interactive Panel Discussion #4 (16:15-16:45) Zili Li
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.